Fulgent Genetics, Inc. (FLGT) vs Myriad Genetics, Inc. (MYGN)

Fulgent Genetics, Inc. and Myriad Genetics, Inc. are both Diagnostics & Research companies. Fulgent Genetics, Inc. is the larger, with a market value of $593.0M against $396.0M — 1.5× the size. Fulgent Genetics, Inc. grew revenue faster over the last twelve months: 6.83% against −3.16%. Myriad Genetics, Inc. has the higher net margin (−14.0% vs −26.1%) and the lower return on invested capital (−19.9% vs −10.3%). Across the 18 metrics below, Fulgent Genetics, Inc. leads on 9 and Myriad Genetics, Inc. on 9.

Valuation

Metric FLGT MYGN Diagnostics & Research median
P/E n/m n/m 33.95
P/S 1.92 0.49 4.87
P/B 0.62 1.30 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 1.18 0.57 5.66
Earnings yield (12.70%) (28.54%) (1.75%)
Free cash flow yield (16.69%) (3.59%) (0.13%)

Profitability

Metric FLGT MYGN Diagnostics & Research median
Gross margin 35.58% 68.83% 50.89%
Operating margin (37.75%) (12.22%) (8.57%)
Net margin (26.05%) (13.96%) (6.37%)
Free cash flow margin (32.04%) (1.76%) 0.00%
Return on equity (8.01%) (32.54%) (2.92%)
Return on assets (7.37%) (17.11%) (6.71%)
Return on invested capital (10.34%) (19.92%) 0.00%

Growth

Metric FLGT MYGN Diagnostics & Research median
Revenue growth (TTM) 6.83% (3.16%) 7.69%
EPS growth (last fiscal year) (39.72%) (180.14%) —
Revenue growth, 5-year CAGR (5.21%) 3.61% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FLGT MYGN Diagnostics & Research median
Debt to equity 0.00 0.40 0.11
Current ratio 6.34 2.21 2.02
Net debt to EBITDA 4.66 2.11 0.78

Dividend

Metric FLGT MYGN Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric FLGT MYGN Diagnostics & Research median
Market cap 592.95m 395.99m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack